Herantis Pharma – executive interview

Herantis Pharma is a Finland-based clinical-stage biotechnology company focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases. Its lead programme is HER-096, a peptide therapeutic, which is currently being assessed in a Phase Ib trial for Parkison’s disease (PD). In this interview, Antti Vuolanto, CEO of Herantis, discusses the progress of HER-096 in the clinic to date, the external validation the company has received through grants and non-dilutive funding, as well as the commercial potential of a disease-modifier for PD. He also covers the key catalysts and milestones that investors should watch out for across the next 12–18 months.

< Previous

You may also be interested in these:

Healthcare

10.04.25

Actinogen Medical – equity proposition

Healthcare

02.04.25

Mendus – equity proposition

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Equities

Equities by Sector

Sectors

Thematics

Latest

Hybrid Air Vehicles – Redefining air travel and air freight

The humanoid revolution walking your way: How robots are stepping out of science fiction

From gold to gold miners: Extracting higher returns in the current bull run

Audiovisual

Latest